Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3821-3824

  Hao, Ting ^a   Feng, Wei ^a   Zhang, Jie ^b   Sun, Yong Jian ^c   Wang, Gang ^c  

^a The Second Affiliated Hospital of Inner Mongolia Medical University   (China)

^b The First Hospital of Huhhot   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

China; Cisplain treatment; ERCC1; ERCC2; Osteosarcoma; Polymorphisms; Survival

Indexed keywords

EID: 84873614801     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3821     Document Type: Article

References (13)

1. American Cancer Society (2007). Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society. Available at: http://www.cancer.org/downloads/STT/ Global_Cancer_Facts_and_Figures_2007_rev.pdf. Oct. 2011.
2. Baek SK, Kim SY, Lee JJ, et al (2006). Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat, 38, 19-24.
3. Caronia D, Patiño-García A, Milne RL, et al (2009).Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J, 9, 347-53.
4. Cao C, Zhang YM, Wang R, et al (2011). Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis. Chin Med J (Engl), 124, 2203-8.
5. Faivre S, Chan D, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37.
6. Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev, 11, 1513-30.
7. Ishibashi K, Okada N, Tajima Y, et al (2011). Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2(ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase(MTHFD) in the primary lesion of colorectal cancer. Gan To Kagaku Ryoho, 38, 2220-3.
8. Le Deley MC, Guinebretiere JM, Gentet JC, et al (2007). Societe Francaise d'Oncologie Pediatrique (SFOP). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer, 43, 752-61.
9. Lu XF, Yang WL, Wan ZH, et al (2011).Glutathione S-transferase polymorphisms and bone tumor risk in China. Asian Pac J Cancer Prev, 12, 3357-60.
10. Rajaraman P, Bhatti P, Doody MM, et al (2008). Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer, 123, 2713-6.
11. Reed E (2005). ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res, 11, 6100-2.
12. Rouissi K, Bahria IB, Bougatef K, et al (2011). The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer, 11, 101.
13. Sun JM, Ahn MJ, Park MJ, et al (2011). Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys, 80, 655-60.